SCHEMBL2491302

SCHEMBL2491302

COc1ccc(-c2ccn[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 1/20 0.43
RARB P10826 1/20 0.43
RARG P13631 1/20 0.43
ERBB2 P04626 2/20 0.41
EGFR P00533 1/20 0.41
KDM4E B2RXH2 4/20 0.39
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
PDE4A P27815 3/20 0.36
PDE4B Q07343 3/20 0.36
PDE4C Q08493 3/20 0.36
PDE4D Q08499 3/20 0.36
LMNA P02545 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
HSD17B10 Q99714 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6832471 0.79 PTGS2 (0.38) ERBB2EGFRKDM4ENPC1RAB9A
SCHEMBL6766113 0.78 PTGS2 (0.37) ERBB2EGFRKDM4ENPC1RAB9A
SCHEMBL6765715 0.78 ERBB2 (0.44) ERBB2EGFRKDM4ENPC1RAB9A
SCHEMBL5067708 0.78 ALDH1A1 (0.53) KDM4EHSD17B10ALDH1A1CYP3A4GAA
SCHEMBL1543223 0.77 CYP3A4 (0.47) RARARARBRARGERBB2EGFR
SCHEMBL8380198 0.76 PDE4B (0.57) KDM4ENPC1RAB9APDE4APDE4B
SCHEMBL11218489 0.74 NOTUM (0.42) KDM4ELMNAKMT2AALDH1A1CYP3A4
SCHEMBL5070316 0.74 CHEK1 (0.51)
SCHEMBL10352726 0.74 RARA (0.61) RARARARBRARGERBB2KDM4E
SCHEMBL14484688 0.73 SCN4A (0.59) KDM4ENPC1RAB9ALMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379534-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-10-26 EP claimed
WO-2010072598-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 WO claimed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US claimed
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS RFC1, RRP1B, RRBP1 RARA 798/4885RARB 584/4885RARG 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.